LHC-CIDI-5 in Hong Kong
Launched by THE UNIVERSITY OF HONG KONG · Jan 27, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new tool called the life history calendar (LHC) to help improve the way we assess mental health disorders in Hong Kong. The LHC is designed to assist people in recalling important life events, which can make it easier to accurately report experiences with mental health issues. By combining this tool with a standard questionnaire known as the CIDI-5, researchers hope to better identify conditions like depression, anxiety, and substance use disorders compared to using the questionnaire alone.
To participate in this study, individuals must be at least 25 years old, have lived in Hong Kong for at least six months in the past year, and be able to read and communicate in Chinese or English. If you decide to join, you can expect to answer questions about your mental health and life experiences in a supportive environment. This trial aims to ensure that mental health assessments are more precise, which can lead to better understanding and treatment options for those in need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters
- • Live in the address sampled from the Census and Statistics Department List of Quarters
- • Reside in Hong Kong for at least six months in the past year
- • Able to read and communicate in Chinese or English
- • Without linguistic or cognitive difficulties
- Exclusion Criteria:
- • Domestic workers
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Sar, , Hong Kong
Patients applied
Trial Officials
Michael Y. Ni, MD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported